ThesisOpen Access

Cyfra 21-1 as a serum tumor marker for follow up of patients with laryngeal and hypopharyngeal squamous cell carcinoma

Thumbnail Image

Files

dhas.pdf (1.39 MB)

Date

2010-01-26

Authors

Publisher

Philipps-Universität Marburg
DOI

item.page.supervisor-of-thesis

Abstract

AIM: To evaluate the importance and potential of Cyfra21-1 as a tumor marker (TM) for follow-up of patients with squamous cell carcinoma (SCC) in laryngeal and hypopharyngeal cancer. PATIENTS AND METHODS: Cyfra21-1 serum levels of 50 patients with laryngeal and hypopharyngeal SCC were evaluated by ECLIA assay. Statistical analysis was performed using Kruskal-Wallis and Jonckheere-Terpstra tests. RESULTS: There was no significant correlation between Cyfra21-1 levels at the time of initial diagnosis and the clinicopathological parameters. The clinical performance of Cyfra 21-1 as an individual tumor marker for follow-up of patients was good. This is shown by the area under the curve (0.873) of their receiver operating characteristic curves. The sensitivity and specificity of Cyfra 21-1 at a cut-off 3.3 ng/ml ere 61.1% and 96.9% respectively. CONCLUSION: Cyfra 21-1 is not suitable for early diagnosis of SCC of the larynx and hypopharynx. An abrupt increase of Cyfra 21-1 in serial measurements indicates impending disease progression in individual patients.

Review

Metadata

Contributors
Supervisor:
Dates
Created: 2009Issued: 2010-01-26Updated: 2011-08-10
Faculty
Medizin
Language
eng
Data types
DoctoralThesis
Keywords
MarkersTumor
DDC-Numbers
610
License
https://rightsstatements.org/vocab/InC-NC/1.0/
URI
https://open.uni-marburg.de/handle/10.17192/z2009.0796
show more
Al-Shagahin, Hani: Cyfra 21-1 as a serum tumor marker for follow up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. : Philipps-Universität Marburg 2010-01-26. DOI: https://doi.org/10.17192/z2009.0796.

License

item.page.license.under-copyright
This item has been published with the following license: In Copyright